| REVIEW ARTICLE |
|
| Year : 2018 | Volume
: 30
| Issue : 1 | Page : 1-4 |
|
|
Evidence-based review and appraisal of the use of droperidol in the emergency department
Pei-Chun Lai1, Yen-Ta Huang2
1 Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation; School of Medicine, Tzu Chi University, Hualien, Taiwan
2 Division of Experimental Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation; Department of Pharmacology, Tzu Chi University, Hualien, Taiwan
Correspondence Address:
Dr. Yen-Ta Huang
Division of Experimental Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, 707, Section 3, Chung-Yang Road, Hualien
Taiwan
 Source of Support: None, Conflict of Interest: None  | 4 |
DOI: 10.4103/tcmj.tcmj_195_17
|
|
|
Droperidol is a short-acting, potent dopamine D2 antagonist that can pass through the blood–brain barrier. A black box warning was issued for droperidol by the United States Food and Drug Administration in 2001 because of a risk of development of torsades de pointes induced by QT prolongation. Many experts feel that the incidence of arrhythmia is overestimated, and low-dose droperidol is almost always used by anesthesiologists for postoperative nausea and vomiting. In this review, we used evidence-based analysis to appraise high-quality studies with a low risk of bias published after 2001 on the use of droperidol in the emergency department (ED). Droperidol appears not only efficacious but also safe to treat patients with nausea/vomiting, acute psychosis, and migraine in the ED. For these conditions, droperidol may be an option for shared decision-making.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
